chartexchange

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

GlobeNewswire Inc. | Nov 12, 2026 4:05 PM EST

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment 

Read original article